Jump to ContentJump to Main Navigation
Adverse EventsRace, Inequality, and the Testing of New Pharmaceuticals$
Users without a subscription are not able to see the full content.

Jill A. Fisher

Print publication date: 2020

Print ISBN-13: 9781479877997

Published to NYU Press Scholarship Online: January 2021

DOI: 10.18574/nyu/9781479877997.001.0001

Show Summary Details
Page of

PRINTED FROM NYU Press SCHOLARSHIP ONLINE (www.nyu.universitypressscholarship.com). (c) Copyright University of NYU Press Press, 2021. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in NYSO for personal use.date: 28 July 2021

The Dark Side of the Model

The Dark Side of the Model

Chapter:
(p.151) 6 The Dark Side of the Model
Source:
Adverse Events
Author(s):

Jill A. Fisher

Publisher:
NYU Press
DOI:10.18574/nyu/9781479877997.003.0007

The clinic practices that make healthy volunteers into model organisms also raise important validity concerns about Phase I trials. Chapter 6 concentrates particularly on the ways in which healthy volunteers, clinics, and the pharmaceutical industry all have incentives to make investigational drugs appear safer than they really might be. The chapter considers intrinsic validity concerns, extrinsic validity concerns, and adverse event reporting as a validity calamity. Intrinsic concerns have to do with the sex, race/ethnicity, age, and seriality of healthy volunteers and raise the question of whether and to what extent healthy volunteers can be considered representative of the general population. Extrinsic concerns include staff and healthy volunteer practices, such as treating the inclusion-exclusion criteria for studies as more malleable than intended or failing to adhere to or enforce the waiting period before healthy volunteers can enroll in their next study. The chapter concludes with a treatment of adverse event reporting as an in-depth case of validity problems that emerge in clinical trials when all the actors have an economic interest in underreporting any symptoms that occur in healthy volunteers during these studies.

Keywords:   Phase I trials, healthy volunteers, research staff, pharmaceutical industry, validity, adverse event, economic interests, model organism

NYU Press Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.